Intended Use

Tempus ECG-AF is intended for use to analyze recordings of 12-lead ECG devices and detect signs associated with a patient experiencing atrial fibrillation and/or atrial flutter within the next 12 months in patients 65 years or older without prior history of AF.

Technology

Tempus ECG-AF uses a locked machine-learning model to analyze standard 12-lead resting ECG recordings collected by FDA-authorized ECG machines from GE and Philips with a sampling rate of 500 Hz. It processes input ECG data, patient age, and sex to generate an uncalibrated risk score, which is thresholded to a binary risk classification, and outputs the result via standard communication protocols to other medical systems for clinical decision support.

Performance

Clinical performance was validated in a retrospective study with 4017 patients aged 65 and older, showing sensitivity of 31%, specificity of 92%, positive predictive value (PPV) of 19%, and negative predictive value (NPV) of 95% for predicting atrial fibrillation within 12 months. The model was trained on over 1.5 million ECGs and validated on multi-site data including various ECG machines.

Predicate Devices

No predicate devices specified

Ready to Sharpen Your Edge?

Subscribe to join 7,600+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.